Stonehearth Capital Management LLC cut its holdings in shares of CVS Health Co. (NYSE:CVS – Get Rating) by 24.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,668 shares of the pharmacy operator’s stock after selling 841 shares during the period. Stonehearth Capital Management LLC’s holdings in CVS Health were worth $270,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also bought and sold shares of the company. Acropolis Investment Management LLC lifted its holdings in shares of CVS Health by 77.1% in the first quarter. Acropolis Investment Management LLC now owns 3,018 shares of the pharmacy operator’s stock valued at $305,000 after purchasing an additional 1,314 shares in the last quarter. Glassy Mountain Advisors Inc. lifted its holdings in shares of CVS Health by 1.1% in the first quarter. Glassy Mountain Advisors Inc. now owns 72,680 shares of the pharmacy operator’s stock valued at $7,356,000 after purchasing an additional 825 shares in the last quarter. Zeke Capital Advisors LLC increased its position in shares of CVS Health by 31.7% in the third quarter. Zeke Capital Advisors LLC now owns 12,182 shares of the pharmacy operator’s stock valued at $1,034,000 after acquiring an additional 2,933 shares during the last quarter. Auxier Asset Management increased its position in shares of CVS Health by 1.0% in the third quarter. Auxier Asset Management now owns 108,859 shares of the pharmacy operator’s stock valued at $9,238,000 after acquiring an additional 1,093 shares during the last quarter. Finally, Farmers & Merchants Investments Inc. increased its position in shares of CVS Health by 1.5% in the fourth quarter. Farmers & Merchants Investments Inc. now owns 263,517 shares of the pharmacy operator’s stock valued at $27,184,000 after acquiring an additional 3,894 shares during the last quarter. Hedge funds and other institutional investors own 78.00% of the company’s stock.
In other news, EVP Daniel P. Finke sold 55,359 shares of the business’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $100.13, for a total transaction of $5,543,096.67. Following the completion of the transaction, the executive vice president now directly owns 3,098 shares in the company, valued at approximately $310,202.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Prem S. Shah sold 16,954 shares of the business’s stock in a transaction on Friday, April 8th. The shares were sold at an average price of $105.00, for a total transaction of $1,780,170.00. Following the transaction, the executive vice president now owns 43,453 shares of the company’s stock, valued at $4,562,565. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 77,659 shares of company stock valued at $7,882,993. 0.69% of the stock is currently owned by company insiders.
CVS Health (NYSE:CVS – Get Rating) last posted its earnings results on Wednesday, May 4th. The pharmacy operator reported $2.22 EPS for the quarter, topping the consensus estimate of $2.14 by $0.08. CVS Health had a net margin of 2.67% and a return on equity of 15.33%. The firm had revenue of $76.83 billion for the quarter, compared to analysts’ expectations of $75.30 billion. During the same quarter last year, the firm earned $2.04 EPS. The company’s quarterly revenue was up 11.2% compared to the same quarter last year. Analysts predict that CVS Health Co. will post 8.34 EPS for the current year.
A number of analysts recently issued reports on CVS shares. Deutsche Bank Aktiengesellschaft lifted their target price on CVS Health from $110.00 to $113.00 in a research report on Thursday, May 5th. StockNews.com started coverage on CVS Health in a research report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Loop Capital started coverage on CVS Health in a research report on Thursday, June 16th. They issued a “buy” rating and a $120.00 target price on the stock. Sanford C. Bernstein downgraded CVS Health from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $122.00 to $112.00 in a research report on Thursday, May 26th. Finally, Tigress Financial upped their target price on CVS Health from $122.00 to $125.00 in a research report on Thursday, April 7th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $116.05.
About CVS Health (Get Rating)
CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.
- Get a free copy of the StockNews.com research report on CVS Health (CVS)
- Worthington’s Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
- Here’s Why Boeing (NYSE: BA) Is Worth The Risk
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.